Novartis CEO Vas Narasimhan sat down with ‘Money Movers’ for an exclusive interview to discuss the company’s strong guidance, the potential for pricing friction in the U.S. market, and other key issues.
Narasimhan highlighted the company’s focus on innovation, particularly in areas such as oncology, immunology, and neuroscience, as key drivers of its strong performance. He also emphasized the importance of digitalization and data analytics in transforming healthcare and improving patient outcomes.
Regarding the potential for pricing friction in the U.S., Narasimhan acknowledged the challenges but expressed confidence in the company’s ability to navigate the complexities of the market. He emphasized the need for collaboration between industry, government, and payers to ensure access to affordable and innovative medicines for patients.
Narasimhan also discussed the company’s commitment to sustainability and its plans to achieve net zero emissions by 2025. He highlighted the importance of reducing the environmental impact of healthcare operations and partnering with suppliers to drive sustainable practices throughout the supply chain.
Overall, the interview provided valuable insights into the strategic priorities and challenges facing Novartis under Narasimhan’s leadership. The company’s focus on innovation, digitalization, sustainability, and patient-centricity is expected to continue shaping its long-term growth and success in the healthcare industry.
